Volkswagen Fails To Compete

It’s been a rough year for automakers, which continued today with Germany’s Volkswagen. 😨

The automobile company owns several brands, including Porsche, Audi, and its original brand, Volkswagen. However, the company’s CEO told staff at an internal meeting that its original brand is “no longer competitive” and that cuts are coming.

Like others in the industry, the parent company VW Group has been working to improve the financial performance of the Volkswagen brand to help fund its shift toward electric vehicles. Although the VW brand had the highest sales volumes, its operating profit margins remain well below its other mass-market brands. đŸ”ģ

CEO Thomas Schaefer said, “With many of our pre-existing structures, processes, and high costs, we are no longer competitive as the Volkswagen brand.”

VW Group hopes to raise the VW brand’s return on sales (ROS) from last year’s 3.6% to 6.5% by 2026, primarily driven by cost-cutting and better differentiation in the marketplace. The company will look to take advantage of its workforce’s “demographic curve,” using early or partial retirement agreements to trim its bloated staff levels. đŸ”ē

Overall, the VW Group is looking to implement a nearly $11 billion savings program, which will have to include broad measures beyond headcount cuts. And it certainly needs to figure it out soon if it’s going to sustain the necessary support for its electric-vehicle push.

Its U.S.-listed ADR is trading back at more than 13-year lows as investors await executives’ plan to balance profitability and an electric-vehicle transition. 📉

Additionally, shares of Albermarle, the largest U.S. provider of lithium for electric vehicle batteries, fell another 6% today. The Global X Lithium and Battery Tech ETF ($LIT) continues its precipitous decline as consumers move away from electric vehicles, causing its inventories to climb far more than anticipated. đŸĒĢ

If the transition to electric vehicles wasn’t already difficult enough for traditional automakers, increased labor costs and lower consumer affordability have put additional pressure on all of the industry’s players. 🙃

A Chip Off The Holiday News Flow

It’s a slow week in the market, but as usual, there’s some news out of the semiconductor space. Let’s take a look. 👀

First up is Israel granting Intel $3.2 billion to support the company’s biggest investment in the country. Intel will not only build a $25 billion factory that creates thousands of jobs but will also buy $16.6 billion in goods and services from Israeli suppliers over the next decade. It is anticipated that the plant will open in 2028 and operate through at least 2035. 🏭

Read It

Adobe Leads Day Of Breakups

Most of today’s stories were related to hookups in the market, but we also need to touch on some major breakups. 💔

The first and most prevalent news story was that Adobe and Figma have called off their $20 billion acquisition. The two companies have faced intense scrutiny from European regulators, today saying, “There is no clear path to receive necessary regulatory approvals from the European Commission and the U.K. Competition and Markets Authority.” ❌

Read It

March Madness Continues At NYCB

When regular people talk about March Madness, they’re referring to college basketball. But when traders and investors talk about March Madness, they’re referring to a regional bank stock imploding.

We’re about a year out from three regional banks failing and/or being rescued, and now the sharks are circling New York Community Bancorp. The long story short, until today, is that the regional lender has too much commercial real estate exposure, weak internal controls over financial reporting, and a new CEO trying to right the ship. 🗞ī¸

Read It

Biotech Buyout Spree Continues

It may be the last week of the year, but many companies are rushing to get deals done before year-end. Two significant transactions in the biotech space were announced today, so let’s dive in. 👇

The first deal involves RayzeBio, which raised $358 million via an initial public offering (IPO) just three months ago. However, its time as a public company is being cut short by Bristol Myers Squibb, which is acquiring the radiopharmaceutical therapeutics company for $62.50 per share in cash. 💰

Read It